Logo
Rejeunesse Fine (1 x 1.1 ml)

Rejeunesse Fine (1 x 1.1 ml)

Rejeunesse

Dermal filler
  • CE Marked Class III medical device according to information from brand and distributors (e.g., CE 1370 certification for Rejeunesse Fine with lidocaine).
  • Manufactured in South Korea by Newmedic Co., Ltd. under applicable medical device quality Management standards (e.g., ISO Based systems for dermal filler production).
  • Uses proprietary cross Linking and purification technology (such as UPHEC) to minimise residual BDDE and endotoxin levels and enhance safety.
  • Non Animal Based hyaluronic acid filler produced in accordance with relevant international and regional regulations for injectable dermal fillers.
Cross-linked hyaluronic acid filler for fine to medium facial wrinkles and contouring

Description

Rejeunesse Fine is a sterile, pyrogen-free, 100% cross-linked hyaluronic acid dermal filler with lidocaine, designed for the correction of fine to medium facial wrinkles, superficial folds, and subtle contouring of the face and neck. The monophasic, viscoelastic gel contains non-animal hyaluronic acid at 24 mg/ml with 0.3% lidocaine to improve patient comfort during injection. It is injected into the superficial to mid dermis to smooth fine lines (such as periorbital, perioral, and forehead lines), refine lip contours, and gently restore lost volume while maintaining a natural look. The filler is intended for professional use only in adults (18+) who are not pregnant, breastfeeding, or allergic to its components.

Bnefits

  • Targets fine to medium wrinkles and superficial folds of the face and neck for a smoother, more youthful appearance.
  • Provides subtle volume restoration and contouring of facial features, including lips and facial outline.
  • Formulated with 24 mg/ml cross-linked, non-animal hyaluronic acid for long-lasting yet natural results.
  • Contains 0.3% lidocaine to reduce pain and discomfort during and immediately after injection.
  • High viscoelasticity and cohesivity support even distribution and stability in the superficial to mid dermis.
  • Non-animal origin HA and advanced purification technology (e.g., UPHEC) minimise residual BDDE and endotoxin levels.
  • Transparent, monophasic gel that is double sterilised for enhanced safety.
  • Clinical effect typically lasts around 8–12 months, depending on area treated, technique, and patient factors.

Indications

  • Prevention and correction of superficial wrinkles in the periorbital region (crow’s feet).
  • Treatment of fine to medium facial wrinkles and nasolabial folds.
  • Correction of forehead and glabellar (frown) lines, where appropriate.
  • Perioral line softening and lip contour correction.
  • Subtle lip volume enhancement in suitable patients.
  • Modelling and gentle contouring of the face and neck in superficial to mid dermal layers.
  • General improvement of skin smoothness and fine-line reduction in indicated facial areas.

Composition

  • Cross-linked hyaluronic acid (sodium hyaluronate) 24 mg/ml, non-animal origin.
  • Lidocaine hydrochloride 0.3% (3 mg/ml) as a local anaesthetic.
  • Phosphate-buffered saline.
  • Water for injections.
  • Trace amounts of BDDE (1,4-butanediol diglycidyl ether) as the crosslinking agent, with residual levels minimised by proprietary purification technology.

Formulation

  • Sterile, transparent, pyrogen-free, monophasic viscoelastic gel.
  • 100% cross-linked hyaluronic acid of non-animal origin.
  • Contains 0.3% lidocaine for pain reduction during injection.
  • Designed for superficial to mid dermal injection.
  • Medical device intended for professional use only.

Packaging

  • Box containing 1 pre-filled glass syringe with 1.1 ml of cross-linked hyaluronic acid gel.
  • Usually supplied with 1 sterile disposable needle (commonly 30G; needle gauge may vary by distributor).
  • Syringe and needle packed in sterile blister packaging.
  • Package insert / instructions for use (IFU).
  • Traceability labels for medical records and patient documentation.

Usage

  • For professional use only: injections must be performed by a suitably trained and licensed healthcare professional experienced in dermal filler techniques.
  • Review the patient’s medical history, indications, and expectations; assess contraindications and obtain informed consent prior to treatment.
  • Cleanse and disinfect the treatment area thoroughly using appropriate antiseptic methods.
  • Inject Rejeunesse Fine into the superficial to mid dermis using appropriate techniques (e.g., linear threading, serial puncture, fanning) according to the treated area and desired result.
  • For fine lines (periorbital, perioral, forehead), inject small amounts along or across the wrinkle in the superficial dermis, releasing the product while withdrawing the needle.
  • For nasolabial folds and medium wrinkles, inject into the mid dermis along the fold, depositing small aliquots evenly while avoiding overcorrection.
  • For lip contouring and subtle lip augmentation, inject along the vermilion border and/or into the lip body in small volumes, taking care to avoid intravascular injection.
  • Inject slowly with gentle, steady pressure and aspirate cautiously where clinically appropriate to reduce the risk of intravascular injection.
  • After injection, gently massage the treated area as needed to ensure uniform distribution and smooth contour, unless contraindicated.
  • Do not overcorrect; it is safer to perform touch-ups at a later visit than to inject excessive volume in one session.
  • Advise patients to avoid makeup on treated areas for several hours post-treatment and to avoid saunas, extreme temperatures, and strenuous exercise for at least 24 hours or as per IFU and clinic protocol.
  • Always refer to and follow the full instructions for use (IFU) supplied with the product for detailed directions, warnings, and precautions.

Contraindications

  • Known hypersensitivity or allergy to hyaluronic acid, lidocaine, other amide-type local anaesthetics, or any component of the formulation.
  • Patients with a history of severe anaphylactic reactions or multiple severe allergies.
  • Presence of active skin infection, inflammation, herpes, or other dermatologic disease at or near the intended injection site.
  • Autoimmune diseases or immunocompromised conditions, unless the treating physician judges the procedure appropriate after risk–benefit evaluation.
  • Bleeding disorders, coagulation abnormalities, or use of anticoagulant or antiplatelet medications that significantly increase bleeding risk, unless carefully evaluated by a physician.
  • Pregnancy and breastfeeding (not recommended due to lack of safety data).
  • Patients under 18 years of age.
  • Previous permanent fillers or foreign bodies in the same region where there is risk of interaction, unless assessed by an experienced practitioner.
  • Do not inject into blood vessels, into areas with compromised blood supply, or into areas with active inflammatory or infectious processes.
  • Any general contraindications to hyaluronic acid dermal fillers or local anaesthetics as determined by the treating healthcare professional.

Adverse Effects

  • Common, usually transient injection-site reactions such as redness (erythema), swelling (oedema), tenderness, pain, itching, or warmth.
  • Bruising or haematoma at the injection site.
  • Temporary lumps, nodules, or palpable product in the treated area, often improving with gentle massage or spontaneously over time.
  • Mild irregularities or asymmetry in the treated area, which may require adjustment or touch-up.
  • Transient firmness or induration in the injection area.
  • Skin discoloration or mild pigment changes around the treated site.
  • Delayed inflammatory or hypersensitivity reactions (e.g., prolonged swelling, erythema, induration), which may require medical management.
  • Infection at the injection site if aseptic technique is not strictly adhered to.
  • Rare but serious complications associated with intravascular injection of fillers, including tissue ischaemia or necrosis, and embolic events potentially affecting vision (e.g., visual disturbance, blindness) or causing stroke; these require immediate emergency management.
  • Allergic or toxic reactions to lidocaine in susceptible individuals, including systemic manifestations of local anaesthetic toxicity.
  • Any unexpected, persistent, or severe adverse reaction should prompt urgent evaluation by a qualified healthcare professional.

Storage Conditions

  • Store in the original packaging to protect from light and contamination until use.
  • Keep at controlled room temperature as specified in the IFU (typically between 2 °C and 25 °C).
  • Do not freeze.
  • Protect from direct sunlight and sources of excessive heat.
  • Do not use after the expiry date printed on the packaging.
  • Use only if the syringe, blister, and packaging are intact and the gel appears homogeneous and free from visible particles.
  • Single-use medical device: do not resterilise and do not reuse any opened or partially used syringe.

Duration

The aesthetic effect typically lasts around 8\u201312 months in most patients, depending on the treatment area, injection technique, individual metabolism, and lifestyle factors. Maintenance or touch-up treatments may be carried out at the clinician\u2019s discretion to prolong results.

Onset

Visible improvement is usually immediate after injection owing to the volumizing and hydrating effect of the gel, with final results becoming more apparent over the next few days as any initial swelling or redness subsides.

Browse more Dermal filler

Top Treatments

Top Cities in the UK